Tue, Sep 23, 2014, 6:43 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Genomic Health Inc. Message Board

  • stupid_hobo73 stupid_hobo73 Aug 6, 2009 11:11 AM Flag

    S&P

    Reiterates BUY opinion on GHDX but lowers 12mo price target to $23 from $26 on revised price-to-sales analysis.

    3rd qtr loss was .04 more than they projected and revs were slightly lower. New full year 2009 estimate lowered by .09 to -.42 and 2010 full year estimate lowered by .12 to +.22 per share.

    S&P cited higher sales and marketing costs and a recessionary impact on tests delivered for their changes.

    They remain positive on OncoType DX's long term prospects.

 
GHDX
28.65-0.84(-2.83%)Sep 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.